Organisation paid for research Program year 2021 Source: CMS Open Payments

Aim Trials Forth Worth

Neither a doctor nor a teaching hospital

Research payments

$1,164

3 payments

Through program year 2021, Aim Trials Forth Worth is reported as receiving $1,164 in research payments, across 3 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$765	1
2020	Research	$302	1
2019	Research	$97	1

Breakdown

Who paid Research payments · program years 2019–2021

Merck Sharp & Dohme Corporation $1,164 3 payments

Studies the money was for Research payments · program years 2019–2021

A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU DAY. $765 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. $399 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.